BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Amiot A, Grimaud J, Peyrin-biroulet L, Filippi J, Pariente B, Roblin X, Buisson A, Stefanescu C, Trang-poisson C, Altwegg R, Marteau P, Vaysse T, Bourrier A, Nancey S, Laharie D, Allez M, Savoye G, Moreau J, Gagniere C, Vuitton L, Viennot S, Aubourg A, Pelletier A, Bouguen G, Abitbol V, Bouhnik Y, Amiot A, Gagniere C, Grimaud J, Peyrin-biroulet L, Zallot C, Bigard M, Filippi J, Hebuterne X, Pariente B, Nachury M, Desreumaux P, Roblin X, Del Tedesco E, Buisson A, Bommelaer G, Stefanescu C, Boureille A, Trang-poisson C, Altwegg R, Marteau P, Dray X, Carbonnel F, Seksik P, Beaugerie L, Cosnes J, Sokol H, Landman C, Nancey S, Boschetti G, Laharie D, Poullenot F, Allez M, Gornet J, Baudry C, Savoye G, Moreau J, Gagniere C, Vuitton L, Koch S, Viennot S, Aubourg A, Picon L, Pelletier A, Sickersen G, Bouguen G, Abitbol V, Chaussade S, Bouhnik Y, Nahon S, Winkfield B, Brixi-benmansour H, Gincul R, Barberis J, Bonaz B, Michiels C, Zerbib F, de Beauregard MB, Locher C, Davin-couve S, Poirette A, Guillem L, Stetiu-mocanu M, Beorchia S, Al Qaddi J. Effectiveness and Safety of Vedolizumab Induction Therapy for Patients With Inflammatory Bowel Disease. Clinical Gastroenterology and Hepatology 2016;14:1593-1601.e2. [DOI: 10.1016/j.cgh.2016.02.016] [Cited by in Crossref: 120] [Cited by in F6Publishing: 114] [Article Influence: 20.0] [Reference Citation Analysis]
Number Citing Articles
1 Battat R, Ma C, Jairath V, Khanna R, Feagan BG. Benefit–Risk Assessment of Vedolizumab in the Treatment of Crohn’s Disease and Ulcerative Colitis. Drug Saf 2019;42:617-32. [DOI: 10.1007/s40264-018-00783-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
2 Shim HH, Chan PW, Chuah SW, Schwender BJ, Kong SC, Ling KL. A review of vedolizumab and ustekinumab for the treatment of inflammatory bowel diseases. JGH Open 2018;2:223-34. [PMID: 30483594 DOI: 10.1002/jgh3.12065] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
3 Chang S, Hudesman D. First-Line Biologics or Small Molecules in Inflammatory Bowel Disease: a Practical Guide for the Clinician. Curr Gastroenterol Rep 2020;22:7. [PMID: 32002688 DOI: 10.1007/s11894-020-0745-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
4 Zhang RF, Liu S, Wang YW, Li J. Potential molecular biomarkers used to predict the response to biological therapies in ulcerative colitis. Chin Med J (Engl) 2021;134:1058-60. [PMID: 33538506 DOI: 10.1097/CM9.0000000000001390] [Reference Citation Analysis]
5 Strik AS, Berends SE, Löwenberg M. Therapeutic drug monitoring-based dosing of TNF inhibitors in inflammatory bowel disease: the way forward? Expert Rev Clin Pharmacol 2019;12:885-91. [PMID: 31305158 DOI: 10.1080/17512433.2019.1642745] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
6 Christensen B, Micic D, Gibson PR, Yarur A, Bellaguarda E, Corsello P, Gaetano JN, Kinnucan J, Rao VL, Reddy S, Singh S, Pekow J, Rubin DT. Vedolizumab in patients with concurrent primary sclerosing cholangitis and inflammatory bowel disease does not improve liver biochemistry but is safe and effective for the bowel disease. Aliment Pharmacol Ther 2018;47:753-62. [PMID: 29377235 DOI: 10.1111/apt.14525] [Cited by in Crossref: 38] [Cited by in F6Publishing: 31] [Article Influence: 9.5] [Reference Citation Analysis]
7 Restellini S, Khanna R, Afif W. Therapeutic Drug Monitoring With Ustekinumab and Vedolizumab in Inflammatory Bowel Disease. Inflamm Bowel Dis 2018;24:2165-72. [PMID: 29788272 DOI: 10.1093/ibd/izy134] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
8 Gemayel NC, Rizzello E, Atanasov P, Wirth D, Borsi A. Dose escalation and switching of biologics in ulcerative colitis: a systematic literature review in real-world evidence. Current Medical Research and Opinion 2019;35:1911-23. [DOI: 10.1080/03007995.2019.1631058] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
9 Hashim A, Patten PEM, Kuhnl A, Ooft ML, Hayee B, Sanderson R. Colitis After CAR T-Cell Therapy for Refractory Large B-Cell Lymphoma Responds to Anti-Integrin Therapy. Inflamm Bowel Dis 2021;27:e45-6. [PMID: 33252123 DOI: 10.1093/ibd/izaa320] [Reference Citation Analysis]
10 Cross RK, Chiorean M, Vekeman F, Xiao Y, Wu E, Chao J, Wang AW. Assessment of the real-world safety profile of vedolizumab using the United States Food and Drug Administration adverse event reporting system. PLoS One 2019;14:e0225572. [PMID: 31800627 DOI: 10.1371/journal.pone.0225572] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
11 Cummings F, Gaya DR, Levison S, Subramanian S, Owen G, Rathmell A, Glen F, Demuth D, Meadowcroft S, Irving PM. A retrospective observational study of early experiences of vedolizumab treatment for inflammatory bowel disease in the UK: The REVIVE study. Medicine (Baltimore) 2019;98:e14681. [PMID: 30817598 DOI: 10.1097/MD.0000000000014681] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 White JR, Din S, Ingram RJM, Foley S, Alam MA, Robinson R, Francis R, Tucker E, Jalal M, Elphick D, Atallah E, Norman A, Amin M, Sajjad A, Heggs N, Meadowcroft S, Moran GW. Experiences of using vedolizumab in the treatment of inflammatory bowel disease in the East Midlands UK – a retrospective observational study. Scandinavian Journal of Gastroenterology 2020;55:907-16. [DOI: 10.1080/00365521.2020.1790647] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
13 Crooks B, Barnes T, Limdi JK. Vedolizumab in the treatment of inflammatory bowel disease: evolving paradigms. Drugs Context. 2020;9:2019-10. [PMID: 32180822 DOI: 10.7573/dic.2019-10-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
14 Kim J, Yoon H, Kim N, Lee KM, Jung SA, Choi CH, Kim ES, Jung Y, Eun CS, Kim TO, Kang SB, Kim YS, Seo GS, Lee CK, Im JP, Park SJ, Park DI, Ye BD. Clinical Outcomes and Response Predictors of Vedolizumab Induction Treatment for Korean Patients With Inflammatory Bowel Diseases Who Failed Anti-TNF Therapy: A KASID Prospective Multicenter Cohort Study. Inflamm Bowel Dis 2021:izaa361. [PMID: 33501935 DOI: 10.1093/ibd/izaa361] [Reference Citation Analysis]
15 Lamb CA, Kennedy NA, Raine T, Hendy PA, Smith PJ, Limdi JK, Hayee B, Lomer MCE, Parkes GC, Selinger C, Barrett KJ, Davies RJ, Bennett C, Gittens S, Dunlop MG, Faiz O, Fraser A, Garrick V, Johnston PD, Parkes M, Sanderson J, Terry H;  IBD guidelines eDelphi consensus group; Gaya DR, Iqbal TH, Taylor SA, Smith M, Brookes M, Hansen R, Hawthorne AB. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut. 2019;68:s1-s106. [PMID: 31562236 DOI: 10.1136/gutjnl-2019-318484] [Cited by in Crossref: 361] [Cited by in F6Publishing: 297] [Article Influence: 120.3] [Reference Citation Analysis]
16 Gubatan J, Keyashian K, Rubin SJS, Wang J, Buckman CA, Sinha S. Anti-Integrins for the Treatment of Inflammatory Bowel Disease: Current Evidence and Perspectives. Clin Exp Gastroenterol 2021;14:333-42. [PMID: 34466013 DOI: 10.2147/CEG.S293272] [Reference Citation Analysis]
17 Kopylov U, Ron Y, Avni-Biron I, Koslowsky B, Waterman M, Daher S, Ungar B, Yanai H, Maharshak N, Ben-Bassat O. Efficacy and Safety of Vedolizumab for Induction of Remission in Inflammatory Bowel Disease-the Israeli Real-World Experience. Inflamm Bowel Dis. 2017;23:404-408. [PMID: 28178003 DOI: 10.1097/mib.0000000000001039] [Cited by in Crossref: 57] [Cited by in F6Publishing: 26] [Article Influence: 14.3] [Reference Citation Analysis]
18 Biemans VBC, van der Woude CJ, Dijkstra G, van der Meulen-de Jong AE, Oldenburg B, de Boer NK, Löwenberg M, Srivastava N, Bodelier AGL, West RL, Jansen JM, de Vries AC, Haans JJL, de Jong DJ, Pierik MJ, Hoentjen F. Vedolizumab for Inflammatory Bowel Disease: Two-Year Results of the Initiative on Crohn and Colitis (ICC) Registry, A Nationwide Prospective Observational Cohort Study: ICC Registry - Vedolizumab. Clin Pharmacol Ther 2020;107:1189-99. [PMID: 31677154 DOI: 10.1002/cpt.1712] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
19 Tadbiri S, Peyrin-Biroulet L, Serrero M, Filippi J, Pariente B, Roblin X, Buisson A, Stefanescu C, Trang-Poisson C, Altwegg R, Marteau P, Vaysse T, Bourrier A, Nancey S, Laharie D, Allez M, Savoye G, Gilletta C, Gagniere C, Vuitton L, Viennot S, Aubourg A, Pelletier AL, Bouguen G, Abitbol V, Fumery M, Claudepierre P, Bouhnik Y, Amiot A; GETAID OBSERV-IBD study group. Impact of vedolizumab therapy on extra-intestinal manifestations in patients with inflammatory bowel disease: a multicentre cohort study nested in the OBSERV-IBD cohort. Aliment Pharmacol Ther. 2018;47:485-493. [PMID: 29250803 DOI: 10.1111/apt.14419] [Cited by in Crossref: 58] [Cited by in F6Publishing: 48] [Article Influence: 11.6] [Reference Citation Analysis]
20 Hasenoehrl C, Storr M, Schicho R. Cannabinoids for treating inflammatory bowel diseases: where are we and where do we go? Expert Rev Gastroenterol Hepatol 2017;11:329-37. [PMID: 28276820 DOI: 10.1080/17474124.2017.1292851] [Cited by in Crossref: 35] [Cited by in F6Publishing: 36] [Article Influence: 7.0] [Reference Citation Analysis]
21 Meserve J, Dulai P. Predicting Response to Vedolizumab in Inflammatory Bowel Disease. Front Med (Lausanne) 2020;7:76. [PMID: 32300596 DOI: 10.3389/fmed.2020.00076] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
22 Amiot A, Filippi J, Abitbol V, Cadiot G, Laharie D, Serrero M, Altwegg R, Bouhnik Y, Peyrin-biroulet L, Gilletta C, Roblin X, Pineton de Chambrun G, Vuitton L, Bourrier A, Nancey S, Gornet J, Nahon S, Bouguen G, Viennot S, Pariente B, Fumery M; UC-USK-GETAID Study Group. Effectiveness and safety of ustekinumab induction therapy for 103 patients with ulcerative colitis: a GETAID multicentre real-world cohort study. Aliment Pharmacol Ther 2020;51:1039-46. [DOI: 10.1111/apt.15717] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 11.0] [Reference Citation Analysis]
23 Stallmach A, Langbein C, Atreya R, Bruns T, Dignass A, Ende K, Hampe J, Hartmann F, Neurath MF, Maul J, Preiss JC, Schmelz R, Siegmund B, Schulze H, Teich N, von Arnim U, Baumgart DC, Schmidt C. Vedolizumab provides clinical benefit over 1 year in patients with active inflammatory bowel disease - a prospective multicenter observational study. Aliment Pharmacol Ther. 2016;44:1199-1212. [PMID: 27714831 DOI: 10.1111/apt.13813] [Cited by in Crossref: 102] [Cited by in F6Publishing: 95] [Article Influence: 17.0] [Reference Citation Analysis]
24 Naganuma M, Mizuno S, Nanki K, Sugimoto S, Kanai T. Recent trends and future directions for the medical treatment of ulcerative colitis. Clin J Gastroenterol 2016;9:329-36. [DOI: 10.1007/s12328-016-0686-z] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
25 Nakamura M, Yamamura T, Maeda K, Sawada T, Mizutani Y, Ishikawa E, Ohashi A, Kajikawa G, Furukawa K, Ohno E, Honda T, Kawashima H, Ishigami M, Fujishiro M. Refractory Ulcerative Colitis Improved by Scheduled Combination Therapy of Vedolizumab and Granulocyte and Monocyte Adsorptive Apheresis. Intern Med 2020;59:3009-14. [PMID: 32727993 DOI: 10.2169/internalmedicine.5302-20] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
26 De Vos M, Dhooghe B, Vermeire S, Louis E, Mana F, Elewaut A, Bossuyt P, Baert F, Reenaers C, Van Gossum M, Macken E, Ferrante M, Hindryckx P, Dewit O, Holvoet T, Franchimont D; Belgian Inflammatory Bowel Disease Research and Development (BIRD). Efficacy of vedolizumab for induction of clinical response and remission in patients with moderate to severe inflammatory bowel disease who failed at least two TNF antagonists. United European Gastroenterol J 2018;6:439-45. [PMID: 29774158 DOI: 10.1177/2050640617722310] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
27 Dart RJ, Samaan MA, Powell N, Irving PM. Vedolizumab: toward a personalized therapy paradigm for people with ulcerative colitis. Clin Exp Gastroenterol 2017;10:57-66. [PMID: 28424557 DOI: 10.2147/CEG.S110547] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
28 Katsanos KH, Papamichael K, Feuerstein JD, Christodoulou DK, Cheifetz AS. Biological therapies in inflammatory bowel disease: Beyond anti-TNF therapies. Clin Immunol 2019;206:9-14. [PMID: 29545207 DOI: 10.1016/j.clim.2018.03.004] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 6.8] [Reference Citation Analysis]
29 Gisbert JP, Chaparro M. Predictors of Primary Response to Biologic Treatment [Anti-TNF, Vedolizumab, and Ustekinumab] in Patients With Inflammatory Bowel Disease: From Basic Science to Clinical Practice. Journal of Crohn's and Colitis 2020;14:694-709. [DOI: 10.1093/ecco-jcc/jjz195] [Cited by in Crossref: 38] [Cited by in F6Publishing: 31] [Article Influence: 12.7] [Reference Citation Analysis]
30 Fukuda T, Naganuma M, Kanai T. Current new challenges in the management of ulcerative colitis. Intest Res 2019;17:36-44. [PMID: 30678445 DOI: 10.5217/ir.2018.00126] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 5.7] [Reference Citation Analysis]
31 Liefferinckx C, Minsart C, Cremer A, Amininejad L, Tafciu V, Quertinmont E, Tops S, Devière J, Gils A, van Gossum A, Franchimont D. Early vedolizumab trough levels at induction in inflammatory bowel disease patients with treatment failure during maintenance. Eur J Gastroenterol Hepatol 2019;31:478-85. [PMID: 30672828 DOI: 10.1097/MEG.0000000000001356] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 4.7] [Reference Citation Analysis]
32 Calenda G, Keawvichit R, Arrode-Brusés G, Pattanapanyasat K, Frank I, Byrareddy SN, Arthos J, Cicala C, Grasperge B, Blanchard JL, Gettie A, Reimann KA, Ansari AA, Martinelli E. Integrin α4β7 Blockade Preferentially Impacts CCR6+ Lymphocyte Subsets in Blood and Mucosal Tissues of Naive Rhesus Macaques. J Immunol 2018;200:810-20. [PMID: 29196458 DOI: 10.4049/jimmunol.1701150] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 3.2] [Reference Citation Analysis]
33 Zundler S, Fischer A, Schillinger D, Binder MT, Atreya R, Rath T, Lopez-Pósadas R, Voskens CJ, Watson A, Atreya I, Neufert C, Neurath MF. The α4β1 Homing Pathway Is Essential for Ileal Homing of Crohn's Disease Effector T Cells In Vivo. Inflamm Bowel Dis 2017;23:379-91. [PMID: 28221249 DOI: 10.1097/MIB.0000000000001029] [Cited by in Crossref: 50] [Cited by in F6Publishing: 29] [Article Influence: 12.5] [Reference Citation Analysis]
34 Scribano ML. Vedolizumab for inflammatory bowel disease: From randomized controlled trials to real-life evidence. World J Gastroenterol 2018; 24(23): 2457-2467 [PMID: 29930467 DOI: 10.3748/wjg.v24.i23.2457] [Cited by in CrossRef: 39] [Cited by in F6Publishing: 31] [Article Influence: 9.8] [Reference Citation Analysis]
35 Chapuis-Biron C, Bourrier A, Nachury M, Nancey S, Bouhnik Y, Serrero M, Armengol-Debeir L, Buisson A, Tran-Minh ML, Zallot C, Fumery M, Bouguen G, Abitbol V, Viennot S, Chanteloup E, Rajca S, Dib N, Parmentier AL, Peyrin-Biroulet L, Vuitton L;  GETAID BioLAP Study Group. Vedolizumab for perianal Crohn's disease: a multicentre cohort study in 151 patients. Aliment Pharmacol Ther. 2020;51:719-727. [PMID: 32080886 DOI: 10.1111/apt.15665] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
36 Grandinetti T, Biedermann L, Bussmann C, Straumann A, Hruz P. Eosinophilic Gastroenteritis: Clinical Manifestation, Natural Course, and Evaluation of Treatment with Corticosteroids and Vedolizumab. Dig Dis Sci. 2019;. [PMID: 30982212 DOI: 10.1007/s10620-019-05617-3] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 5.7] [Reference Citation Analysis]
37 Amiot A, Serrero M, Peyrin-Biroulet L, Filippi J, Pariente B, Roblin X, Buisson A, Stefanescu C, Trang-Poisson C, Altwegg R, Marteau P, Vaysse T, Bourrier A, Nancey S, Laharie D, Allez M, Savoye G, Moreau J, Vuitton L, Viennot S, Aubourg A, Pelletier AL, Bouguen G, Abitbol V, Gagniere C, Bouhnik Y, OBSERV-IBD study group and the GETAID. One-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multicentre cohort study. Aliment Pharmacol Ther. 2017;46:310-321. [PMID: 28593685 DOI: 10.1111/apt.14167] [Cited by in Crossref: 80] [Cited by in F6Publishing: 73] [Article Influence: 16.0] [Reference Citation Analysis]
38 Schreiber S, Dignass A, Peyrin-Biroulet L, Hather G, Demuth D, Mosli M, Curtis R, Khalid JM, Loftus EV Jr. Systematic review with meta-analysis: real-world effectiveness and safety of vedolizumab in patients with inflammatory bowel disease. J Gastroenterol. 2018;53:1048-1064. [PMID: 29869016 DOI: 10.1007/s00535-018-1480-0] [Cited by in Crossref: 57] [Cited by in F6Publishing: 50] [Article Influence: 14.3] [Reference Citation Analysis]
39 Battat R, Dulai PS, Jairath V, Vande Casteele N. A product review of vedolizumab in inflammatory bowel disease. Hum Vaccin Immunother 2019;15:2482-90. [PMID: 30897022 DOI: 10.1080/21645515.2019.1591139] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
40 Speight RA, Mansfield JC. Editorial: how effective is vedolizumab in the ‘real world’? Aliment Pharmacol Ther 2017;46:555-6. [DOI: 10.1111/apt.14215] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
41 Moeser A, Lerche M, Wirtz H, Stallmach A. [Aspects of pulmonary involvement in inflammatory bowel disease]. Internist (Berl) 2018;59:876-85. [PMID: 30116854 DOI: 10.1007/s00108-018-0473-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
42 Lenti MV, Levison S, Eliadou E, Willert R, Kemp K, Carter A, Stansfield C, Assadsangabi A, Singh S, Crooks B, Tattersall S, Fairhurst F, Kenneth C, Subramanian S, Probert C, Storey D, Gregg B, Smith P, Liu E, Limdi JK, Johnston A, Hamlin PJ, Selinger CP. A real-world, long-term experience on effectiveness and safety of vedolizumab in adult patients with inflammatory bowel disease: The Cross Pennine study. Dig Liver Dis 2018;50:1299-304. [PMID: 30077465 DOI: 10.1016/j.dld.2018.07.007] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 5.0] [Reference Citation Analysis]
43 Dulai PS, Sandborn WJ. Next-Generation Therapeutics for Inflammatory Bowel Disease. Curr Gastroenterol Rep 2016;18:51. [PMID: 27461274 DOI: 10.1007/s11894-016-0522-0] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
44 Schreiner P, Neurath MF, Ng SC, El-Omar EM, Sharara AI, Kobayashi T, Hisamatsu T, Hibi T, Rogler G. Mechanism-Based Treatment Strategies for IBD: Cytokines, Cell Adhesion Molecules, JAK Inhibitors, Gut Flora, and More. Inflamm Intest Dis 2019;4:79-96. [PMID: 31559260 DOI: 10.1159/000500721] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 7.7] [Reference Citation Analysis]
45 Christensen B, Colman RJ, Micic D, Gibson PR, Goeppinger SR, Yarur A, Weber CR, Cohen RD, Rubin DT. Vedolizumab as Induction and Maintenance for Inflammatory Bowel Disease: 12-month Effectiveness and Safety. Inflamm Bowel Dis 2018;24:849-60. [PMID: 29562271 DOI: 10.1093/ibd/izx067] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 6.3] [Reference Citation Analysis]
46 D'Amico F, Danese S, Peyrin-Biroulet L. Vedolizumab and etrolizumab for ulcerative colitis: twins or simple cousins? Expert Opin Biol Ther 2020;20:353-61. [PMID: 31951748 DOI: 10.1080/14712598.2020.1717465] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
47 Manzini R, Schwarzfischer M, Atrott K, Laimbacher A, Lang S, Wawrzyniak M, Rickenbacher A, Turina M, Hruz P, Lissner D, Siegmund B, Rogler G, Scharl M, Spalinger MR. Combination of Vedolizumab With Tacrolimus Is More Efficient Than Vedolizumab Alone in the Treatment of Experimental Colitis. Inflamm Bowel Dis 2021:izab063. [PMID: 33847343 DOI: 10.1093/ibd/izab063] [Reference Citation Analysis]
48 Fiorucci S, Biagioli M, Distrutti E. Immunephenotype Predicts Response to Vedolizumab: Integrating Clinical and Biochemical Biomarkers in the Treatment of Inflammatory Bowel Diseases. Dig Dis Sci 2018;63:2168-71. [PMID: 29611077 DOI: 10.1007/s10620-018-5039-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
49 Park SC, Jeen YT. Anti-integrin therapy for inflammatory bowel disease. World J Gastroenterol 2018; 24(17): 1868-1880 [PMID: 29740202 DOI: 10.3748/wjg.v24.i17.1868] [Cited by in CrossRef: 41] [Cited by in F6Publishing: 32] [Article Influence: 10.3] [Reference Citation Analysis]
50 Pellet G, Stefanescu C, Carbonnel F, Peyrin-Biroulet L, Roblin X, Allimant C, Nachury M, Nancey S, Filippi J, Altwegg R, Brixi H, Fotsing G, de Rosamel L, Shili S, Laharie D; Groupe d'Etude Thérapeutique des Affections Inflammatoires du tube Digestif. Efficacy and Safety of Induction Therapy With Calcineurin Inhibitors in Combination With Vedolizumab in Patients With Refractory Ulcerative Colitis. Clin Gastroenterol Hepatol 2019;17:494-501. [PMID: 30213584 DOI: 10.1016/j.cgh.2018.08.081] [Cited by in F6Publishing: 20] [Reference Citation Analysis]
51 Mühl L, Becker E, Müller TM, Atreya R, Atreya I, Neurath MF, Zundler S. Clinical experiences and predictors of success of treatment with vedolizumab in IBD patients: a cohort study. BMC Gastroenterol 2021;21:33. [PMID: 33482730 DOI: 10.1186/s12876-021-01604-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
52 Ferrante M, de Buck van Overstraeten A, Schils N, Moens A, Van Assche G, Wolthuis A, Vermeire S, D’hoore A. Perioperative Use of Vedolizumab is not Associated with Postoperative Infectious Complications in Patients with Ulcerative Colitis Undergoing Colectomy. Journal of Crohn's and Colitis 2017;11:1353-61. [DOI: 10.1093/ecco-jcc/jjx095] [Cited by in Crossref: 41] [Cited by in F6Publishing: 36] [Article Influence: 8.2] [Reference Citation Analysis]
53 Zezos P, Kabakchiev B, Weizman AV, Nguyen GC, Narula N, Croitoru K, Steinhart AH, Silverberg MS. Ulcerative Colitis Patients Continue to Improve Over the First Six Months of Vedolizumab Treatment: 12-Month Clinical and Mucosal Healing Effectiveness. J Can Assoc Gastroenterol 2020;3:74-82. [PMID: 32328546 DOI: 10.1093/jcag/gwy065] [Reference Citation Analysis]
54 Nasonov EL, Abdulganieva DI, Fairushina IF. The use of Tofacitinib in the treatment of inflammatory bowel disease. Ter Arkh 2019;91:101-8. [PMID: 31094180 DOI: 10.26442/00403660.2019.02.000155] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
55 Baker MC, Weng Y, Fairchild R, Ahuja N, Rohatgi N. Comparison of Adverse Events Among Home- vs Facility-Administered Biologic Infusions, 2007-2017. JAMA Netw Open 2021;4:e2110268. [PMID: 34081140 DOI: 10.1001/jamanetworkopen.2021.10268] [Reference Citation Analysis]
56 Naganuma M, Sugimoto S, Fukuda T, Mitsuyama K, Kobayashi T, Yoshimura N, Ohi H, Tanaka S, Andoh A, Ohmiya N, Saigusa K, Yamamoto T, Morohoshi Y, Ichikawa H, Matsuoka K, Hisamatsu T, Watanabe K, Mizuno S, Abe T, Suzuki Y, Kanai T; INDIGO Study Group. Indigo naturalis is effective even in treatment-refractory patients with ulcerative colitis: a post hoc analysis from the INDIGO study. J Gastroenterol 2020;55:169-80. [PMID: 31529220 DOI: 10.1007/s00535-019-01625-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
57 Lightner AL, Tse CS, Potter DD Jr, Moir C. Postoperative outcomes in vedolizumab-treated pediatric patients undergoing abdominal operations for inflammatory bowel disease. J Pediatr Surg 2018;53:1706-9. [PMID: 29111083 DOI: 10.1016/j.jpedsurg.2017.09.019] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
58 Macaluso FS, Orlando R, Fries W, Scolaro M, Magnano A, Pluchino D, Cappello M, Morreale GC, Siringo S, Privitera AC. The real-world effectiveness of vedolizumab on intestinal and articular outcomes in inflammatory bowel diseases. Dig Liver Dis. 2018; Epub ahead of print. [PMID: 29576495 DOI: 10.1016/j.dld.2018.02.013] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 5.8] [Reference Citation Analysis]
59 Ibraheim H, Samaan MA, Srinivasan A, Brain O, Digby-Bell J, Irving PM, Norman I, Jawad I, Biedermann J, Ibarra A, Kok KB, Parkes G, Rimmer J, Compot E, Parkes M, Segal J, Oppong P, Hart A, Hayee B, Powell N. Effectiveness and safety of vedolizumab in inflammatory bowel disease patients aged 60 and over: an observational multicenter UK experience. Ann Gastroenterol 2020;33:170-7. [PMID: 32127738 DOI: 10.20524/aog.2020.0447] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
60 Wehkamp J, Stange EF. Recent advances and emerging therapies in the non-surgical management of ulcerative colitis. F1000Res 2018;7:F1000 Faculty Rev-1207. [PMID: 30135722 DOI: 10.12688/f1000research.15159.1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 2.8] [Reference Citation Analysis]
61 Miyoshi J, Maeda T, Matsuoka K, Saito D, Miyoshi S, Matsuura M, Okamoto S, Tamura S, Hisamatsu T. Machine learning using clinical data at baseline predicts the efficacy of vedolizumab at week 22 in patients with ulcerative colitis. Sci Rep 2021;11:16440. [PMID: 34385588 DOI: 10.1038/s41598-021-96019-x] [Reference Citation Analysis]
62 Debnath P, Rathi PM. Vedolizumab in Inflammatory Bowel Disease: West versus East. Inflamm Intest Dis 2021;6:1-17. [PMID: 33850834 DOI: 10.1159/000512805] [Reference Citation Analysis]
63 Scarozza P, De Cristofaro E, Scucchi L, Rocchetti I, Marafini I, Neri B, Salvatori S, Biancone L, Calabrese E, Monteleone G. Effect of Vedolizumab on Anemia of Chronic Disease in Patients with Inflammatory Bowel Diseases. J Clin Med 2020;9:E2126. [PMID: 32640680 DOI: 10.3390/jcm9072126] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
64 Iborra M, Beltrán B, Maroto N, Navarro-cortés P, Boscá-watts M, Ferrer-bradley I, García-morales N, Sáez-gonzález E, Hinojosa J, Mínguez M, Nos P. Vedolizumab, una opción en pacientes con enfermedad inflamatoria intestinal intolerantes a tiopurinas y refractarios a biológicos. Gastroenterología y Hepatología 2018;41:535-43. [DOI: 10.1016/j.gastrohep.2018.06.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
65 Novak G, Hindryckx P, Khanna R, Jairath V, Feagan BG. The safety of vedolizumab for the treatment of ulcerative colitis.Expert Opin Drug Saf. 2017;16:501-507. [PMID: 28276855 DOI: 10.1080/14740338.2017.1300251] [Cited by in Crossref: 25] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
66 Banerjee R, Chuah SW, Hilmi IN, Wu DC, Yang SK, Demuth D, Lindner D, Adsul S. Efficacy and safety of vedolizumab in Crohn's disease in patients from Asian countries in the GEMINI 2 study. Intest Res 2021;19:83-94. [PMID: 33378612 DOI: 10.5217/ir.2019.09160] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
67 Townsend T, Razanskaite V, Dodd S, Storey D, Michail S, Morgan J, Davies M, Penman D, Watters C, Swaminathan M, Sabine J, Chapman A, Smith PJ, Flanagan PK, Reilly I, Bodger K, Subramanian S. Comparative effectiveness of ustekinumab or vedolizumab after one year in 130 patients with anti-TNF-refractory Crohn's disease. Aliment Pharmacol Ther 2020;52:1341-52. [PMID: 32955122 DOI: 10.1111/apt.16057] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
68 Dragoni G, Bagnoli S, Le Grazie M, Campani C, Rogai F, Manetti N, Bensi C, Macrì G, Galli A, Milla M. Long-term efficacy and safety of vedolizumab in patients with inflammatory bowel diseases: A real-life experience from a tertiary referral center. J Dig Dis 2019;20:235-42. [PMID: 30927309 DOI: 10.1111/1751-2980.12748] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
69 Cassinotti A, Batticciotto A, Parravicini M, Lombardo M, Radice P, Cortelezzi CC, Segato S, Zanzi F, Cappelli A, Segato S. Evidence-based efficacy of methotrexate in adult Crohn's disease in different intestinal and extraintestinal indications. Therap Adv Gastroenterol 2022;15:17562848221085889. [PMID: 35340755 DOI: 10.1177/17562848221085889] [Reference Citation Analysis]
70 Battat R, Dulai PS, Vande Casteele N, Evans E, Hester KD, Webster E, Jain A, Proudfoot JA, Mairalles A, Neill J, Singh S, Chang JT, Rivera-Nieves J, Sandborn WJ, Boland BS. Biomarkers Are Associated With Clinical and Endoscopic Outcomes With Vedolizumab Treatment in Ulcerative Colitis. Inflamm Bowel Dis 2019;25:410-20. [PMID: 30295781 DOI: 10.1093/ibd/izy307] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 7.5] [Reference Citation Analysis]
71 Zingone F, Barberio B, Compostella F, Girardin G, D'Incà R, Marinelli C, Marsilio I, Lorenzon G, Savarino EV. Good efficacy and safety of vedolizumab in Crohn's disease and ulcerative colitis in a real-world scenario. Therap Adv Gastroenterol 2020;13:1756284820936536. [PMID: 32695231 DOI: 10.1177/1756284820936536] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
72 Annese V, Nathwani R, Alkhatry M, Al-Rifai A, Al Awadhi S, Georgopoulos F, Jazzar AN, Khassouan AM, Koutoubi Z, Taha MS, Limdi JK. Optimizing biologic therapy in inflammatory bowel disease: a Delphi consensus in the United Arab Emirates. Therap Adv Gastroenterol 2021;14:17562848211065329. [PMID: 34987611 DOI: 10.1177/17562848211065329] [Reference Citation Analysis]
73 Engel T, Yung DE, Ma C, Pariente B, Wils P, Eliakim R, Ungar B, Ben-horin S, Kopylov U. Effectiveness and safety of Ustekinumab for Crohn's disease; systematic review and pooled analysis of real-world evidence. Digestive and Liver Disease 2019;51:1232-40. [DOI: 10.1016/j.dld.2019.05.002] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 8.3] [Reference Citation Analysis]
74 Ungar B, Kopylov U, Yavzori M, Fudim E, Picard O, Lahat A, Coscas D, Waterman M, Haj-natour O, Orbach-zingboim N, Mao R, Chen M, Chowers Y, Eliakim R, Ben-horin S. Association of Vedolizumab Level, Anti-Drug Antibodies, and α4β7 Occupancy With Response in Patients With Inflammatory Bowel Diseases. Clinical Gastroenterology and Hepatology 2018;16:697-705.e7. [DOI: 10.1016/j.cgh.2017.11.050] [Cited by in Crossref: 65] [Cited by in F6Publishing: 62] [Article Influence: 16.3] [Reference Citation Analysis]
75 Nakase H, Uchino M, Shinzaki S, Matsuura M, Matsuoka K, Kobayashi T, Saruta M, Hirai F, Hata K, Hiraoka S, Esaki M, Sugimoto K, Fuji T, Watanabe K, Nakamura S, Inoue N, Itoh T, Naganuma M, Hisamatsu T, Watanabe M, Miwa H, Enomoto N, Shimosegawa T, Koike K. Evidence-based clinical practice guidelines for inflammatory bowel disease 2020. J Gastroenterol 2021;56:489-526. [PMID: 33885977 DOI: 10.1007/s00535-021-01784-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 8.0] [Reference Citation Analysis]
76 Scarozza P, Marafini I, Laudisi F, Troncone E, Schmitt H, Lenti MV, Costa S, Rocchetti I, De Cristofaro E, Salvatori S, Frezzati L, Di Sabatino A, Atreya R, Neurath MF, Calabrese E, Monteleone G. Extent of Mucosal Inflammation in Ulcerative Colitis Influences the Clinical Remission Induced by Vedolizumab. J Clin Med 2020;9:E385. [PMID: 32024071 DOI: 10.3390/jcm9020385] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
77 Reinglas J, Gonczi L, Verdon C, Bessissow T, Afif W, Wild G, Seidman E, Bitton A, Lakatos PL. Low Rate of Drug Discontinuation, Frequent Need for Dose Adjustment, and No Association with Development of New Arthralgia in Patients Treated with Vedolizumab: Results from a Tertiary Referral IBD Center. Dig Dis Sci 2020;65:2046-53. [PMID: 31813132 DOI: 10.1007/s10620-019-05982-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
78 Banerjee R, Ali RAR, Wei SC, Adsul S. Biologics for the Management of Inflammatory Bowel Disease: A Review in Tuberculosis-Endemic Countries. Gut Liver 2020;14:685-98. [PMID: 33191310 DOI: 10.5009/gnl19209] [Reference Citation Analysis]
79 Andrew RE, Messaris E. Update on medical and surgical options for patients with acute severe ulcerative colitis: What is new? World J Gastrointest Surg 2016; 8(9): 598-605 [PMID: 27721922 DOI: 10.4240/wjgs.v8.i9.598] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
80 Engel T, Ungar B, Yung DE, Ben-Horin S, Eliakim R, Kopylov U. Vedolizumab in IBD-Lessons From Real-world Experience; A Systematic Review and Pooled Analysis. J Crohns Colitis. 2018;12:245-257. [PMID: 29077833 DOI: 10.1093/ecco-jcc/jjx143] [Cited by in Crossref: 74] [Cited by in F6Publishing: 72] [Article Influence: 18.5] [Reference Citation Analysis]
81 Moulton CD, Pavlidis P, Norton C, Norton S, Pariante C, Hayee B, Powell N. Depressive symptoms in inflammatory bowel disease: an extraintestinal manifestation of inflammation? Clin Exp Immunol 2019;197:308-18. [PMID: 30762873 DOI: 10.1111/cei.13276] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 9.0] [Reference Citation Analysis]
82 Zundler S, Becker E, Weidinger C, Siegmund B. Anti-Adhesion Therapies in Inflammatory Bowel Disease-Molecular and Clinical Aspects. Front Immunol. 2017;8:891. [PMID: 28804488 DOI: 10.3389/fimmu.2017.00891] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 7.0] [Reference Citation Analysis]
83 Eriksson C, Rundquist S, Lykiardopoulos V, Udumyan R, Karlén P, Grip O, Söderman C, Almer S, Hertervig E, Marsal J, Gunnarsson J, Malmgren C, Delin J, Strid H, Sjöberg M, Öberg D, Bergemalm D, Hjortswang H, Halfvarson J; SWIBREG SVEAH Study Group. Real-world effectiveness of vedolizumab in inflammatory bowel disease: week 52 results from the Swedish prospective multicentre SVEAH study. Therap Adv Gastroenterol 2021;14:17562848211023386. [PMID: 34276808 DOI: 10.1177/17562848211023386] [Reference Citation Analysis]
84 Stevens TW, Matheeuwsen M, Lönnkvist MH, Parker CE, Wildenberg ME, Gecse KB, D’haens GR. Systematic review: predictive biomarkers of therapeutic response in inflammatory bowel disease-personalised medicine in its infancy. Aliment Pharmacol Ther 2018;48:1213-31. [DOI: 10.1111/apt.15033] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 4.5] [Reference Citation Analysis]
85 Shi HY, Ng SC. The state of the art on treatment of Crohn's disease. J Gastroenterol. 2018;53:989-998. [PMID: 29980848 DOI: 10.1007/s00535-018-1479-6] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
86 Biancone L, Annese V, Ardizzone S, Armuzzi A, Calabrese E, Caprioli F, Castiglione F, Comberlato M, Cottone M, Danese S, Daperno M, D’incà R, Frieri G, Fries W, Gionchetti P, Kohn A, Latella G, Milla M, Orlando A, Papi C, Petruzziello C, Riegler G, Rizzello F, Saibeni S, Scribano ML, Vecchi M, Vernia P, Meucci G, Aratari A, Bossa F, Cappello M, Cassinotti A, Chiriatti A, Fiorino G, Formica V, Guidi L, Losco A, Mocciaro F, Onali S, Pastorelli L, Pica R, Principi M, Renna S, Ricci C, Rispo A, Rogai F, Sarmati L, Scaldaferri F, Spina L, Tambasco R, Testa A, Viscido A. Safety of treatments for inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). Digestive and Liver Disease 2017;49:338-58. [DOI: 10.1016/j.dld.2017.01.141] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 5.2] [Reference Citation Analysis]
87 Guan Q, Zhang J. Recent Advances: The Imbalance of Cytokines in the Pathogenesis of Inflammatory Bowel Disease. Mediators Inflamm 2017;2017:4810258. [PMID: 28420941 DOI: 10.1155/2017/4810258] [Cited by in Crossref: 51] [Cited by in F6Publishing: 60] [Article Influence: 10.2] [Reference Citation Analysis]
88 Ledder O, Assa A, Levine A, Escher JC, de Ridder L, Ruemmele F, Shah N, Shaoul R, Wolters VM, Rodrigues A, Uhlig HH, Posovszky C, Kolho KL, Jakobsen C, Cohen S, Shouval DS, de Meij T, Martin-de-Carpi J, Richmond L, Bronsky J, Friedman M, Turner D. Vedolizumab in Paediatric Inflammatory Bowel Disease: A Retrospective Multi-Centre Experience From the Paediatric IBD Porto Group of ESPGHAN. J Crohns Colitis 2017;11:1230-7. [PMID: 28605483 DOI: 10.1093/ecco-jcc/jjx082] [Cited by in Crossref: 45] [Cited by in F6Publishing: 32] [Article Influence: 11.3] [Reference Citation Analysis]
89 Samaan MA, Pavlidis P, Johnston E, Warner B, Digby-Bell J, Koumoutsos I, Fong S, Goldberg R, Patel K, Gulati S. Vedolizumab: early experience and medium-term outcomes from two UK tertiary IBD centres. Frontline Gastroenterol. 2017;8:196-202. [PMID: 28839909 DOI: 10.1136/flgastro-2016-100720] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 4.2] [Reference Citation Analysis]
90 Coletta M, Paroni M, Alvisi MF, De Luca M, Rulli E, Mazza S, Facciotti F, Lattanzi G, Strati F, Abrignani S, Fantini MC, Vecchi M, Geginat J, Caprioli F. Immunological Variables Associated With Clinical and Endoscopic Response to Vedolizumab in Patients With Inflammatory Bowel Diseases. J Crohns Colitis 2020;14:1190-201. [PMID: 32100016 DOI: 10.1093/ecco-jcc/jjaa035] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
91 Dubinsky MC. Reviewing treatments and outcomes in the evolving landscape of ulcerative colitis. Postgraduate Medicine 2017;129:538-53. [DOI: 10.1080/00325481.2017.1319730] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
92 Fuchs F, Schillinger D, Atreya R, Hirschmann S, Fischer S, Neufert C, Atreya I, Neurath MF, Zundler S. Clinical Response to Vedolizumab in Ulcerative Colitis Patients Is Associated with Changes in Integrin Expression Profiles. Front Immunol 2017;8:764. [PMID: 28717358 DOI: 10.3389/fimmu.2017.00764] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 5.8] [Reference Citation Analysis]
93 Yu Y, Chen J, Zhang X, Wang Y, Wang S, Zhao L, Wang Y. Identification of anti-inflammatory compounds from Zhongjing formulae by knowledge mining and high-content screening in a zebrafish model of inflammatory bowel diseases. Chin Med 2021;16:42. [PMID: 34059101 DOI: 10.1186/s13020-021-00452-z] [Reference Citation Analysis]
94 Kopylov U, Verstockt B, Biedermann L, Sebastian S, Pugliese D, Sonnenberg E, Steinhagen P, Arebi N, Ron Y, Kucharzik T, Roblin X, Ungar B, Shitrit AB, Ardizzone S, Molander P, Coletta M, Peyrin-Biroulet L, Bossuyt P, Avni-Biron I, Tsoukali E, Allocca M, Katsanos K, Raine T, Sipponen T, Fiorino G, Ben-Horin S, Eliakim R, Armuzzi A, Siegmund B, Baumgart DC, Kamperidis N, Maharshak N, Maaser C, Mantzaris G, Yanai H, Christodoulou DK, Dotan I, Ferrante M. Effectiveness and Safety of Vedolizumab in Anti-TNF-Naïve Patients With Inflammatory Bowel Disease-A Multicenter Retrospective European Study. Inflamm Bowel Dis 2018;24:2442-51. [PMID: 29788318 DOI: 10.1093/ibd/izy155] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 10.0] [Reference Citation Analysis]
95 Crowell KT, Tinsley A, Williams ED, Coates MD, Bobb A, Koltun WA, Messaris E. Vedolizumab as a rescue therapy for patients with medically refractory Crohn's disease. Colorectal Dis 2018;20:905-12. [PMID: 29673053 DOI: 10.1111/codi.14225] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
96 Johnson CM, Dassopoulos T. Update on the Use of Thiopurines and Methotrexate in Inflammatory Bowel Disease. Curr Gastroenterol Rep 2018;20. [DOI: 10.1007/s11894-018-0658-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
97 Engel T, Kopylov U. Ustekinumab in Crohn’s disease: evidence to date and place in therapy. Ther Adv Chronic Dis. 2016;7:208-214. [PMID: 27433311 DOI: 10.1177/2040622316653306] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.7] [Reference Citation Analysis]
98 Ye BD, Cheon JH, Song KH, Kim JS, Kim YH, Yoon H, Lee KM, Kang SB, Jang BI, Park JJ, Kim TO, Lee DW, Foo CY, Shin JE, Park DI. The real-world outcomes of vedolizumab in patients with ulcerative colitis in Korea: a multicenter retrospective study. Therap Adv Gastroenterol 2021;14:17562848211024769. [PMID: 34285716 DOI: 10.1177/17562848211024769] [Reference Citation Analysis]
99 Cichoż-Lach H, Michalak A, Kopertowska-Majchrzak M, Eder P, Stawczyk-Eder K, Waszak K, Talar-Wojnarowska R, Zatorski H, Solarska-Półchłopek A, Chmielnicki J, Filip R, Pękala A, Janiak M, Skrobot K, Kasińska E, Krogulecki M, Królikowski P, Kłopocka M, Liebert A, Poniewierka E, Smoła I, Gąsiorowska A, Kaczka A, Wypych J, Wojciechowski K, Drygała S, Zagórowicz E. Characteristics of patients with moderate-to-severe ulcerative colitis treated with vedolizumab: results from a Polish multicenter, prospective, observational real-life study (the POLONEZ study). Therap Adv Gastroenterol 2021;14:17562848211036456. [PMID: 34484422 DOI: 10.1177/17562848211036456] [Reference Citation Analysis]
100 Martin A, Nachury M, Peyrin-biroulet L, Bouhnik Y, Nancey S, Bourrier A, Serrero M, Fumery M, Buisson A, Laharie D, Gilletta C, Filippi J, Allez M, Bouguen G, Roblin X, Altwegg R, Dib N, Pineton de Chambrun G, Savoye G, Carbonnel F, Viennot S, Amiot A, Amiot A, Martin A, Gagnière C, Nachury M, Pariente B, Wils P, Peyrin-biroulet L, Zallot C, Bouhnik Y, Treton X, Stefanescu C, Nancey S, Boschetti G, Seksik P, Beaugerie L, Kirchgesner J, Bourrier A, Sokol H, Serrero M, Fumery M, Yzet C, Brazier F, Laharie D, Rivière P, Poullenot F, Buisson A, Gilletta C, Filippi J, Hebuterne X, Allez M, Gornet J, Bouguen G, Siproudhis L, Roblin X, Altwegg R, Pineton de Chambrun G, Dib N, Savoye G, Carbonnel F, Meyer A, Viennot S, Lebaut G; GETAID-Vedo-STOP Study Group. Maintenance of Remission Among Patients With Inflammatory Bowel Disease After Vedolizumab Discontinuation: A Multicentre Cohort Study. Journal of Crohn's and Colitis 2020;14:896-903. [DOI: 10.1093/ecco-jcc/jjaa005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
101 Garcia-Romero R, Martinez de Zabarte Fernandez JM, Pujol-Muncunill G, Donat-Aliaga E, Segarra-Cantón O, Irastorza-Terradillos I, Medina-Benitez E, Ruiz-Hernández CJ, Carrillo-Palau M, Ros-Arnal I, Rodriguez-Martínez A, Escartin-Madurga L, Gutiérrez-Junquera C, Vicente-Santamaría S, Velasco Rodriguez-Belvis M, Fernández-Fernández S, Alberto-Alonso JR, Montraveta M, Torres-Peral R, Navalon-Rubio M, Navas-López VM, Martin de Carpi J. Safety and effectiveness of vedolizumab in paediatric patients with inflammatory bowel disease: an observational multicentre Spanish study. Eur J Pediatr 2021;180:3029-38. [PMID: 33880650 DOI: 10.1007/s00431-021-04063-6] [Reference Citation Analysis]
102 Barré A, Colombel JF, Ungaro R. Review article: predictors of response to vedolizumab and ustekinumab in inflammatory bowel disease. Aliment Pharmacol Ther 2018;47:896-905. [PMID: 29430672 DOI: 10.1111/apt.14550] [Cited by in Crossref: 64] [Cited by in F6Publishing: 56] [Article Influence: 16.0] [Reference Citation Analysis]
103 Terjung B, Schmelz R, Ehehalt R, Klaus J, Knop J, Schwind S, Wilke T, Stallmach A. Safety of vedolizumab in the treatment of pregnant women with inflammatory bowel disease: a targeted literature review. Therap Adv Gastroenterol 2020;13:1756284820952592. [PMID: 33149762 DOI: 10.1177/1756284820952592] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
104 Pandolfi F, Franza L, Altamura S, Mandolini C, Cianci R, Ansari A, Kurnick JT. Integrins: Integrating the Biology and Therapy of Cell-cell Interactions. Clin Ther 2017;39:2420-36. [PMID: 29203050 DOI: 10.1016/j.clinthera.2017.11.002] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 3.8] [Reference Citation Analysis]
105 Macaluso FS, Fries W, Renna S, Viola A, Muscianisi M, Cappello M, Guida L, Siringo S, Camilleri S, Garufi S, Privitera AC, Belluardo N, Giangreco E, Bertolami C, Vassallo R, Rizzuto G, Orlando R, Ventimiglia M, Orlando A; Sicilian Network for Inflammatory Bowel Disease (SN-IBD). Effectiveness and safety of vedolizumab in biologically naïve patients: A real-world multi-centre study. United European Gastroenterol J 2020;8:1045-55. [PMID: 32772830 DOI: 10.1177/2050640620948802] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
106 Gecse KB, Lakatos PL. IBD in 2016: Biologicals and biosimilars in IBD - the road to personalized treatment. Nat Rev Gastroenterol Hepatol 2017;14:74-6. [PMID: 28074074 DOI: 10.1038/nrgastro.2016.206] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
107 Amiot A, Serrero M, Peyrin-Biroulet L, Filippi J, Pariente B, Roblin X, Buisson A, Stefanescu C, Trang-Poisson C, Altwegg R, Marteau P, Vaysse T, Bourrier A, Nancey S, Laharie D, Allez M, Savoye G, Moreau J, Vuitton L, Viennot S, Bouguen G, Abitbol V, Fumery M, Gagniere C, Bouhnik Y; OBSERV-IBD study group, the GETAID. Three-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multi-centre cohort study. Aliment Pharmacol Ther. 2019;50:40-53. [PMID: 31165509 DOI: 10.1111/apt.15294] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 9.3] [Reference Citation Analysis]
108 Becker E, Schramm S, Binder MT, Allner C, Wiendl M, Neufert C, Atreya I, Neurath M, Zundler S. Dynamic Adhesion Assay for the Functional Analysis of Anti-adhesion Therapies in Inflammatory Bowel Disease. J Vis Exp 2018. [PMID: 30295649 DOI: 10.3791/58210] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
109 Takatsu N, Hisabe T, Higashi D, Ueki T, Matsui T. Vedolizumab in the Treatment of Ulcerative Colitis: An Evidence-Based Review of Safety, Efficacy, and Place of Therapy. Core Evid 2020;15:7-20. [PMID: 32280316 DOI: 10.2147/CE.S179053] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
110 Binder M, Becker E, Wiendl M, Schleier L, Fuchs F, Leppkes M, Atreya R, Neufert C, Atreya I, Neurath MF, Zundler S. Similar Inhibition of Dynamic Adhesion of Lymphocytes From IBD Patients to MAdCAM-1 by Vedolizumab and Etrolizumab-s. Inflammatory Bowel Diseases 2018;24:1237-50. [DOI: 10.1093/ibd/izy077] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
111 Allner C, Melde M, Becker E, Fuchs F, Mühl L, Klenske E, Müller L, Morgenstern N, Fietkau K, Hirschmann S, Atreya R, Atreya I, Neurath MF, Zundler S. Baseline levels of dynamic CD4+ T cell adhesion to MAdCAM-1 correlate with clinical response to vedolizumab treatment in ulcerative colitis: a cohort study. BMC Gastroenterol 2020;20:103. [PMID: 32293299 DOI: 10.1186/s12876-020-01253-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
112 Guzzo C, Ichikawa D, Park C, Phillips D, Liu Q, Zhang P, Kwon A, Miao H, Lu J, Rehm C, Arthos J, Cicala C, Cohen MS, Fauci AS, Kehrl JH, Lusso P. Virion incorporation of integrin α4β7 facilitates HIV-1 infection and intestinal homing. Sci Immunol 2017;2:eaam7341. [PMID: 28763793 DOI: 10.1126/sciimmunol.aam7341] [Cited by in Crossref: 37] [Cited by in F6Publishing: 36] [Article Influence: 7.4] [Reference Citation Analysis]
113 Jin QW, Wang XD. Progress in research of vedolizumab in treatment of inflammatory bowel disease. Shijie Huaren Xiaohua Zazhi 2021; 29(5): 248-255 [DOI: 10.11569/wcjd.v29.i5.248] [Reference Citation Analysis]
114 Wang Y, Wang J, Pekow J, Dalal S, Cohen RD, Ollech J, Israel A, Shogan BD, Micic D, Cannon L, Umanskiy K, Hurst R, Hyman N, Rubin DT, Sakuraba A. Outcome of elective switching to vedolizumab in inflammatory bowel disease patients under tumor necrosis factor antagonist-maintained clinical remission. J Gastroenterol Hepatol 2019;34:2090-5. [PMID: 31169926 DOI: 10.1111/jgh.14751] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
115 Dulai PS, Amiot A, Peyrin-Biroulet L, Jairath V, Serrero M, Filippi J, Singh S, Pariente B, Loftus EV Jr, Roblin X, Kane S, Buisson A, Siegel CA, Bouhnik Y, Sandborn WJ, Lasch K, Rosario M, Feagan BG, Bojic D, Trang-Poisson C, Shen B, Altwegg R, Sands BE, Colombel JF, Carbonnel F; GETAID OBSERV-IBD, VICTORY Cohorts Collaboration*. A clinical decision support tool may help to optimise vedolizumab therapy in Crohn's disease. Aliment Pharmacol Ther 2020;51:553-64. [PMID: 31867766 DOI: 10.1111/apt.15609] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
116 Jacob EM, Borah A, Pillai SC, Kumar DS. Inflammatory Bowel Disease: The Emergence of New Trends in Lifestyle and Nanomedicine as the Modern Tool for Pharmacotherapy. Nanomaterials (Basel) 2020;10:E2460. [PMID: 33316984 DOI: 10.3390/nano10122460] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
117 Chaparro M, Garre A, Ricart E, Iborra M, Mesonero F, Vera I, Riestra S, García-Sánchez V, Luisa De Castro M, Martin-Cardona A, Aldeguer X, Mínguez M, de-Acosta MB, Rivero M, Muñoz F, Andreu M, Bargalló A, González-Muñoza C, Pérez Calle JL, García-Sepulcre MF, Bermejo F, Huguet JM, Cabriada JL, Gutiérrez A, Mañosa M, Villoria A, Carbajo AY, Lorente R, García-López S, Piqueras M, Hinojosa E, Arajol C, Sicilia B, Conesa AM, Sainz E, Almela P, Llaó J, Roncero O, Camo P, Taxonera C, Domselaar MV, Pajares R, Legido J, Madrigal R, Lucendo AJ, Alcaín G, Doménech E, Gisbert JP; GETECCU study group. Short and long-term effectiveness and safety of vedolizumab in inflammatory bowel disease: results from the ENEIDA registry. Aliment Pharmacol Ther 2018;48:839-51. [PMID: 30281832 DOI: 10.1111/apt.14930] [Cited by in Crossref: 43] [Cited by in F6Publishing: 42] [Article Influence: 14.3] [Reference Citation Analysis]
118 Eriksson C, Marsal J, Bergemalm D, Vigren L, Björk J, Eberhardson M, Karling P, Söderman C, Myrelid P, Cao Y, Sjöberg D, Thörn M, Karlén P, Hertervig E, Strid H, Ludvigsson JF, Almer S, Halfvarson J; The SWIBREG Vedolizumab Study Group. Long-term effectiveness of vedolizumab in inflammatory bowel disease: a national study based on the Swedish National Quality Registry for Inflammatory Bowel Disease (SWIBREG). Scandinavian Journal of Gastroenterology 2017;52:722-9. [DOI: 10.1080/00365521.2017.1304987] [Cited by in Crossref: 73] [Cited by in F6Publishing: 69] [Article Influence: 14.6] [Reference Citation Analysis]